Get started
Author

Emily Lichtenstein

Observed names: E. Lichtenstein, Emily A Lichtenstein, Emily A. Lichtenstein, Lichtenstein, Emily
OpenAlex ID: A5113101329
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
2017 · Jennifer E. Amengual, Renee Lichtenstein, et al. · Blood · 134
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
2016 · Lorenzo Falchi, Ahmed Sawas, et al. · Journal of Hematology & Oncology · 48
PDF
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma
2016 · Matko Kalac, Jennifer K. Lue, et al. · British Journal of Haematology · 18
PDF
Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79
2017 · Andrew L. Deng, Yu Ri Kim, et al. · Haematologica · 15
The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience
2015 · Ahmed Sawas, Joseph M. Connors, et al. · Blood · 13
A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)
2017 · Lorenzo Falchi, Jennifer Kimberly Lue, et al. · Blood · 10
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
2023 · Benjamin L. Schlechter, Daniel Olson, et al. · Journal of Clinical Oncology · 7
PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses
2016 · Lorenzo Falchi, Ahmed Sawas, et al. · Blood · 7
Rate of complete metabolic responses to immune checkpoint inhibitors in extremely heavily pre-treated patients with classical Hodgkin’s lymphoma and immunoepigenetic priming.
2016 · Lorenzo Falchi, Ahmed Sawas, et al. · Journal of Clinical Oncology · 5
366 Complete tumor regression of metastatic epithelial cancer following T cell receptor (TCR)-T cell therapy
2025 · Scott M Norberg, Stacey Doran, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
2024 · Benjamin L. Schlechter, Ecaterina Elena Dumbrava, et al. · Journal of Clinical Oncology · 3
PDF
Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development
2015 · Owen A. O'Connor, Kelly Zullo, et al. · Blood · 3
Oral Azacytidine (aza) and Romidepsin (r) Reveals Promising Activity in Patients With Relapsed or Refractory (r/r) Peripheral T‐cell Lymphoma (ptcl)
2017 · O.A. O'Connor, J.K. Lue, et al. · Hematological Oncology · 2
PDF
Development of novel backbones for the treatment of peripheral T-cell lymphoma (PTCL): The pralatrexate/romidepsin doublet.
2016 · Jennifer Effie Amengual, Renee Lichtenstein, et al. · Journal of Clinical Oncology · 2
A Case Series Of Continuous Low Dose Lenalidomide In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma
2013 · Ahmed Sawas, Sean Clark-Garvey, et al. · Blood · 2
A phase II trial of T cell receptor gene therapy targeting HPV-16 E7 for HPV-associated cancers
2024 · Eugenia Girda, Scott Norberg, et al. · Gynecologic Oncology · 1
Abstract B035: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
2023 · Benjamin Schlechter, Ecaterina Dumbrava, et al. · Molecular Cancer Therapeutics · 1
654 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
2023 · Daniel J Olson, Ecaterina Dumbrava, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Updates in Chemotherapy-Induced Nausea and Vomiting: The Oncology Nurse and Oncology Nurse Practitioner's Perspectives
2016 · Ellen A. Neylon, Erin L. Butzen, et al. · Seminars in Oncology Nursing · 1
A feasibility study of E7 TCR-T cell induction therapy for locoregionally advanced HPV associated cancers
2026 · Eugenia Girda, Scott Norberg, et al. · Gynecologic Oncology
1528P A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
2023 · D. Olson, E.E. Dumbrava, et al. · Annals of Oncology
PDF
P-31 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
2023 · E. Dumbrava, D. Olson, et al. · Annals of Oncology
PDF
A Phase 1 Study of Pralatrexate Plus Romidepsin Reveals Marked Activity in Patients With Relapsed or Refractory (r/r) Peripheral T‐cell Lymphoma (ptcl)
2017 · J.E. Amengual, R. Lichtenstein, et al. · Hematological Oncology
PDF
Additional file 2: Table S2. of High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
2016 · Falchi, Lorenzo, Sawas, Ahmed, et al. · Figshare
Additional file 1: Table S1. of High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
2016 · Falchi, Lorenzo, Sawas, Ahmed, et al. · Figshare
Works count: 28
Citation count: 276
H-index: 7
I10-index: 6
Year
Topic
Type